These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37944278)

  • 1. 'Unable to have a proper conversation over the phone about my concerns': a multimethods evaluation of the impact of COVID-19 on routine childhood vaccination services in London, UK.
    Buck E; Burt J; Karampatsas K; Hsia Y; Whyte G; Amirthalingam G; Skirrow H; Le Doare K
    Public Health; 2023 Dec; 225():229-236. PubMed ID: 37944278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.
    Tielemans SMAJ; de Melker HE; Hahné SJM; Boef AGC; van der Klis FRM; Sanders EAM; van der Sande MAB; Knol MJ
    BMJ; 2017 Aug; 358():j3862. PubMed ID: 28855159
    [No Abstract]   [Full Text] [Related]  

  • 3. Measuring the timeliness of childhood vaccinations: Using cohort data and routine health records to evaluate quality of immunisation services.
    Walton S; Cortina-Borja M; Dezateux C; Griffiths LJ; Tingay K; Akbari A; Bandyopadhyay A; Lyons RA; Bedford H
    Vaccine; 2017 Dec; 35(51):7166-7173. PubMed ID: 29132992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timeliness and completeness of routine childhood vaccinations in young children residing in a district with recurrent vaccine-preventable disease outbreaks, Jerusalem, Israel.
    Stein-Zamir C; Israeli A
    Euro Surveill; 2019 Feb; 24(6):. PubMed ID: 30755293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses.
    Zimmermann P; Perrett KP; van der Klis FR; Curtis N
    Immunol Cell Biol; 2019 Jul; 97(6):577-585. PubMed ID: 30791143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
    Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.
    Miller E; Andrews N; Waight P; Findlow H; Ashton L; England A; Stanford E; Matheson M; Southern J; Sheasby E; Goldblatt D; Borrow R
    Clin Vaccine Immunol; 2011 Mar; 18(3):367-72. PubMed ID: 21191076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Zürcher SJ; Signorell A; Léchot-Huser A; Aebi C; Huber CA
    Vaccine; 2023 Nov; 41(48):7226-7233. PubMed ID: 38593195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.
    Stein-Zamir C; Israeli A
    Hum Vaccin Immunother; 2017 Sep; 13(9):2102-2110. PubMed ID: 28696824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
    Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
    MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timeliness of routine immunization in a population-based Italian cohort of very preterm infants: results of the ACTION follow-up project.
    Tozzi AE; Piga S; Corchia C; Di Lallo D; Carnielli V; Chiandotto V; Fertz MC; Miniaci S; Rusconi F; Cuttini M
    Vaccine; 2014 Feb; 32(7):793-9. PubMed ID: 24397902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Zhong Y; Clapham HE; Aishworiya R; Chua YX; Mathews J; Ong M; Wang J; Murugasu B; Chiang WC; Lee BW; Chin HL
    Vaccine; 2021 Jan; 39(5):780-785. PubMed ID: 33414050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
    Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P
    Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
    Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM
    Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
    Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
    BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'.
    Rieckmann A; Hærskjold A; Benn CS; Aaby P; Lange T; Sørup S
    Int J Epidemiol; 2019 Dec; 48(6):2026-2038. PubMed ID: 31062020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of maternal mental illness on vaccination uptake in children: a UK population-based cohort study.
    Osam CS; Pierce M; Hope H; Ashcroft DM; Abel KM
    Eur J Epidemiol; 2020 Sep; 35(9):879-889. PubMed ID: 32328992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine.
    Carmona A; Miranda M; Barrio F; De Vicente A; Mares J; Muñoz E; Diez-Delgado J; Alonso A; Giménez-Sánchez F; Merino J; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2010 Mar; 29(3):269-71. PubMed ID: 19952860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.